MEK inhibitors

1:59
Trametinib: new treatment for recurrent LGSOC
Jonathan Ledermann
1:13
Targeting oncogenes in NSCLC
Kenneth O'Byrne
1:07
Heating up a tumor: modulating the immunoscore
Jerome Galon
4:18
Development of novel treatments in melanoma patients with BRAF mutations
Dirk Schadendorf
1:56
News from ASCO 2016 for melanoma
Jean-Jacques Grob
2:49
The developments of genetic testing and personalized cancer vaccines for patients with skin cancer
Grant McArthur
2:10
Using biomarkers to predict response to combination therapies in BRAF-mutant melanoma
Grant McArthur
2:31
Neoadjuvant therapy with trametinib and dabrafenib in high risk resectable BRAF-mutant melanoma
Rodabe N. Amaria
2:46
Neoadjuvant therapy in bulky Stage III melanoma
Georgina Long
2:10
Combined treatment with BRAF and MEK inhibitors in metastatic melanomas with BRAF mutations
Rodabe N. Amaria
1:48
SECOMBIT – determining the order of sequential therapies in metastatic melanoma with BRAF mutations
Paolo Ascierto
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals